Target intelligence / Profile preview

Major capsid protein L1 of human papillomavirus (type-specific, e.g., HPV-16, HPV-18, HPV-6, HPV-11) (L1)

Target
L1
Molecular classification
Structural protein, Viral capsid protein, Other (not enzyme, receptor, transporter, etc.)
01

Overview

The major capsid protein L1 is the principal structural protein of the human papillomavirus (HPV) and forms the outer shell of the virus, assembling into pentameric capsomeres that further build the icosahedral capsid[1][2][3]. L1 is highly conserved among papillomaviruses, is essential for viral genome encapsidation and stability, and contains major neutralizing epitopes targeted by antibodies that prevent infection[1][3][4]. Recombinant L1 can self-assemble into virus-like particles (VLPs), which are non-infectious but highly immunogenic and serve as the basis for prophylactic HPV vaccines such as Gardasil and Cervarix[2][3][5]. These proteins are not enzymes, receptors, or classical host drug targets but are considered therapeutic targets in the context of vaccine design, where eliciting an antibody response neutralizes the virus and prevents HPV-related diseases, including genital warts and cancers associated with HPV infection[2][3][5].

Other names
HPV L1 proteinPapillomavirus major capsid protein L1L1 capsid proteinL1 major late protein
02

Mechanism of action

Induces production of neutralizing antibodies against HPV via virus-like particle (VLP)-based vaccination Prevents infection by blocking viral entry into host cells

03

Biological functions

Virus assemblyFormation of viral capsidGenome encapsidationImmune recognitionVirus-host cell attachment and entry
04

Disease associations

InfectionCancer (specifically in HPV types causing anogenital and oropharyngeal cancers)
05

Safety considerations

Rare anaphylactic reactions to vaccine components (not target-specific)No direct oncogenicity or toxicity; L1 is non-infectious when used as VLP in vaccines
06

Interacting drugs

Gardasil (HPV vaccine)

1 more in the full profile.

07

Biomarkers

Seropositivity for anti-L1 (evidence of vaccination or prior HPV infection)L1 antibody titers (for vaccine efficacy monitoring)

Beyond the preview

Go deeper on Major capsid protein L1 of human papillomavirus (type-specific, e.g., HPV-16, HPV-18, HPV-6, HPV-11) (L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major capsid protein L1 of human papillomavirus (type-specific, e.g., HPV-16, HPV-18, HPV-6, HPV-11) (L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call